Nine Medical Associations Jointly Signed the Proposal of Pharmaceutical Enterprise Ethical Practices
On 29th October, China Chamber of Commerce for Import & Export of Medicines &Health Products (CCCMHPIE) co-organized ‘Conference on Pharmaceutical Enterprise Ethical Practices in China’ with other 8 medical associations, namely China Pharmaceutical Industry Association(CPIA), China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA), China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC), China Association of Traditional Chinese Medicine, China Association of Pharmaceutical Commerce(CAPC), China Nonprescription Medicines Association(CNMA), China Pharmaceutical Enterprises Promotion Association and China Pharmaceutical Enterprises Culture Construction Association, and jointly signed Pharmaceutical Enterprise Ethical Practices under the guidance of National Bureau of Corruption Prevention, China Food and Drug Administration and State Administration of Traditional Chinese Medicine of the People’s Republic of China.
XU Ming, Vice-president of CCCMHPIE, attended the conference and delivered a speech. He expressed that the release of Pharmaceutical Enterprise Ethical Practices was a significant measure for pharmaceutical industry to strengthen self-restraint and to improve credibility, a strong signal of Chinese pharmaceutical industry’s will to be self-restrained, it would surely improve the healthy development of the industry.
Pharmaceutical Enterprise Ethical Practices signed and implemented on the conference requires the pharmaceutical enterprises to abide by the six principles of the Codes, namely healthcare and patient focus, integrity, independence, legitimate intent, transparency and accountability, to adhere to the terms and conditions of the Codes. Moreover, it appeals the government to continue to strengthen the reformation, administrate by law, raise goodness and punish the evil, purify the market, thus establishing a healthy and ordered healthcare environment for the public by cooperatively standardizing the order of Chinese pharmaceutical market.
The Practices deriving from the joint declaration of APEC released in September 2011, aims to establish and carry out APEC’s codes of ethics in crucial areas. In September, 2012, a professional working team which was composed of industrial compliance specialists, anti-corruption experts, workers of healthy industry and researchers of commercial ethics from APEC’s economic entity put forward codes of business ethics in the biopharmaceutical sector in Mexico, called The Mexico City Principles. Vice-president XU Ming participated in the signing of the Principle. The Mexico City Principles appeals all the stakeholders of biopharmaceutical sector which include enterprises, industrial associations, professional organizations and administration institutions and anti-corruption institutions to support the shared ethics.
